Santhera Restructuring: Discontinues Lead DMD Candidate
Pursuing Financing Options
Switzerland’s Santhera is to restructure its business and seek extra funding after the failure of Puldysa (idebenone) in a Phase III Duchenne muscular dystrophy study at interim analysis.
